FDA Approves RYZUMVI Label Expansion to Presbyopia, Triggering Viatris Milestone
IRD has more than doubled off its 52-week low of $1.7 on light trading volume (0.3× avg).
Summary
The FDA approved Opus Genetics' sNDA for RYZUMVI (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults, expanding the already-marketed mydriasis product into a large U.S. market. The approval triggers a milestone payment from Viatris, which holds U.S. commercialization rights, providing non-dilutive cash without adding sales infrastructure. The label expansion is backed by the VEGA-2 and VEGA-3 Phase 3 trials, which met efficacy endpoints with no treatment-related serious adverse events. This shifts Opus further toward partnered commercial economics and follows the positive OPGx-BEST1 data reported in September. The milestone amount was not disclosed; watch for the size of that payment and Viatris' launch timing and pricing.
At the time of this announcement, IRD was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $325.3M. The 52-week trading range was $1.70 to $7.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.